Clinical Trial Update: This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307. [Phase 3]

View source ↗

Summary

Two-year follow-up from Phase 3 trial CRAD001A2307 evaluating long-term effects in renal transplant recipients who completed the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• CRAD001A2307

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 3 | Status: COMPLETED